BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24005193)

  • 1. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
    Carragee EJ; Chu G; Rohatgi R; Hurwitz EL; Weiner BK; Yoon ST; Comer G; Kopjar B
    J Bone Joint Surg Am; 2013 Sep; 95(17):1537-45. PubMed ID: 24005193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer?
    Malham GM; Giles GG; Milne RL; Blecher CM; Brazenor GA
    Spine (Phila Pa 1976); 2015 Nov; 40(22):1737-42. PubMed ID: 26730525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion.
    Glassman SD; Dimar JR; Carreon LY; Campbell MJ; Puno RM; Johnson JR
    Spine (Phila Pa 1976); 2005 Aug; 30(15):1694-8. PubMed ID: 16094268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
    Lykissas MG; Aichmair A; Sama AA; Hughes AP; Lebl DR; Cammisa FP; Girardi FP
    Spine J; 2014 Feb; 14(2):217-24. PubMed ID: 24269858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.
    Faundez A; Tournier C; Garcia M; Aunoble S; Le Huec JC
    Int Orthop; 2016 Jun; 40(6):1309-19. PubMed ID: 26961193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5 randomized controlled trials: clinical article.
    Burkus JK; Dryer RF; Peloza JH
    J Neurosurg Spine; 2013 Feb; 18(2):112-21. PubMed ID: 23199378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rhBMP-2 for posterolateral instrumented lumbar fusion: a multicenter prospective randomized controlled trial.
    Hurlbert RJ; Alexander D; Bailey S; Mahood J; Abraham E; McBroom R; Jodoin A; Fisher C
    Spine (Phila Pa 1976); 2013 Dec; 38(25):2139-48. PubMed ID: 24296479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk from bone morphogenetic protein exposure in spinal arthrodesis.
    Kelly MP; Savage JW; Bentzen SM; Hsu WK; Ellison SA; Anderson PA
    J Bone Joint Surg Am; 2014 Sep; 96(17):1417-22. PubMed ID: 25187579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
    Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
    Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
    Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies.
    Boden SD; Kang J; Sandhu H; Heller JG
    Spine (Phila Pa 1976); 2002 Dec; 27(23):2662-73. PubMed ID: 12461392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer.
    Sayama C; Willsey M; Chintagumpala M; Brayton A; Briceño V; Ryan SL; Luerssen TG; Hwang SW; Jea A
    J Neurosurg Pediatr; 2015 Jul; 16(1):4-13. PubMed ID: 25860984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
    Villavicencio AT; Burneikiene S
    Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose rhBMP-2 for adults: major and minor complications: a study of 502 spine cases.
    Mesfin A; Buchowski JM; Zebala LP; Bakhsh WR; Aronson AB; Fogelson JL; Hershman S; Kim HJ; Ahmad A; Bridwell KH
    J Bone Joint Surg Am; 2013 Sep; 95(17):1546-53. PubMed ID: 24005194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
    Crawford CH; Carreon LY; McGinnis MD; Campbell MJ; Glassman SD
    Spine (Phila Pa 1976); 2009 Jun; 34(13):1390-4. PubMed ID: 19440166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human bone morphogenetic protein-2 versus iliac crest bone graft in anterior cervical discectomy and fusion: Dysphagia and dysphonia rates in the early postoperative period with review of the literature.
    Riederman BD; Butler BA; Lawton CD; Rosenthal BD; Balderama ES; Bernstein AJ
    J Clin Neurosci; 2017 Oct; 44():180-183. PubMed ID: 28716569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis.
    Dimar JR; Glassman SD; Burkus JK; Pryor PW; Hardacker JW; Carreon LY
    J Bone Joint Surg Am; 2009 Jun; 91(6):1377-86. PubMed ID: 19487515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial.
    Dawson E; Bae HW; Burkus JK; Stambough JL; Glassman SD
    J Bone Joint Surg Am; 2009 Jul; 91(7):1604-13. PubMed ID: 19571082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates.
    Barnes B; Boden SD; Louis-Ugbo J; Tomak PR; Park JS; Park MS; Minamide A
    Spine (Phila Pa 1976); 2005 May; 30(10):1127-33. PubMed ID: 15897825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer follow-up continues to reveal no increased risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion.
    Dettori JR; Chapman JR; DeVine JG; McGuire RA; Junge MR; Norvell DC
    Spine J; 2019 Oct; 19(10):1640-1647. PubMed ID: 31108234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.